Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

1/27, 1:00 PM (Source: GlobeNewswire)

NEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Renalytix’s management is scheduled to participate in a fireside chat on Tuesday, February 15, 2022, at 3:30 p.m. EST. Due to the format of this virtual event the presentation will not be webcast. The company will be available for virtual 1X1 meetings with investors registered for the event.

About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company’s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc www.renalytix.com
James McCullough, CEOVia Walbrook PR
  
Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600
Alex Price / Nicholas Moore 
  
Investec Bank plc (Joint Broker)Tel: 020 7597 4000
Gary Clarence / Daniel Adams 
  
Walbrook PR LimitedTel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne ApplegarthMob: 07980 541 893 / 07584 391 303
  
CapComm Partners 
Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com


Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.